Earth Science Tech Directs Market to Update SIC to Pharmaceutical Preparations, Shedding CBD Tag
Summary
Earth Science Tech, Inc. issued a directive to financial data providers to update its industry classification to pharmaceutical preparations (SIC 2834), formally identifying as a pharmaceutical entity since 2022 and moving away from legacy CBD/cannabis tags.
Key Events
-
Industry Classification Update
The company issued a formal directive to financial data providers, news aggregators, and brokerage platforms to update its industry classification.
-
Formal Pharmaceutical Identification
Earth Science Tech, Inc. formally identifies as a pharmaceutical entity with Primary SIC Code 2834 (Pharmaceutical Preparations) and Primary Sector Healthcare, a strategic pivot initiated in 2022.
-
Removal of Outdated Tags
The directive instructs platforms to remove outdated industry tags related to CBD or cannabis, ensuring market perception aligns with current operations.
-
CEO Emphasizes Accuracy
CEO Giorgio R. Saumat stated that the recent 15c-211 clearance was the final regulatory step, and the company is aggressively moving to ensure the market sees its accurate, pharmaceutical-focused identity.
Analysis
Earth Science Tech, Inc. is taking proactive steps to ensure its industry classification accurately reflects its current operations. By formally directing financial data providers to update its SIC code to 2834 (Pharmaceutical Preparations) and sector to Healthcare, the company aims to align market perception with its strategic pivot initiated in 2022. This move is significant for a micro-cap company as it seeks to shed outdated associations with the CBD/cannabis industry, which can be volatile and subject to different investor sentiment. A clear pharmaceutical identity may attract a broader and more appropriate investor base, potentially improving valuation and access to capital.
At the time of this filing, ETST was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $0.00 to $0.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.